Plain-English translation of NCT07646847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a support program called the Immunotherapy CARE Program to help people with cancer manage side effects from PD-1 or PD(L)-1 checkpoint inhibitors — a type of immunotherapy. The study will compare this new navigation program with standard care to see whether it helps patients stay on their treatment longer and improves their quality of life. Researchers will ask you to answer questionnaires about how you're doing throughout the study.
Immunotherapy can cause difficult side effects that sometimes make people stop their treatment. This study wants to find out whether giving patients extra support, resources, and help navigating side effects keeps them on this medication longer and helps them feel better overall.
You likely qualify if…
You likely don't qualify if…
You will be randomly placed into one of two groups: either the new Immunotherapy CARE Program with personalized support and resource navigation, or enhanced standard care. Throughout the study, you'll complete questionnaires about your quality of life and how well you're managing side effects from the medication. The study team will work with you to understand your basic needs and connect you with resources to help you stay on your treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States